Opioid Overdose Hospitalizations among Medicare-Disability Beneficiaries

References

1. 1.↵
   1. Kenan K,
   2. Mack K,
   3. Paulozzi L

   . Trends in prescriptions for oxycodone and other commonly used opioids in the United States, 2000–2010. Open Med 2012;6:e41–47.

   OpenUrlPubMed
2. 2.↵
   Addressing Prescription Drug Abuse in the United States: Current Activities and Future Opportunities. Washington DC: U.S. Department of Health and Human Services; 2013.
3. 3.↵
   1. Cicero TJ,
   2. Dart RC,
   3. Inciardi JA,
   4. Woody GE,
   5. Schnoll S,
   6. Munoz A

   . The development of a comprehensive risk-management program for prescription opioid analgesics: researched abuse, diversion and addiction-related surveillance (RADARS). Pain Med 2007;8:157–70.

   OpenUrlCrossRefPubMed
4. 4.↵
   1. Davis CS,
   2. Carr D

   . Legal changes to increase access to naloxone for opioid overdose reversal in the United States. Drug Alcohol Depend 2015;157:112–20.

   OpenUrl
5. 5.↵
   1. Heavey SC,
   2. Burstein G,
   3. Moore C,
   4. Homish GG

   . Overdose education and naloxone distribution program attendees: who attends, what do they know, and how do they feel? J Public Health Manag Pract 2018;24:63–68.

   OpenUrl
6. 6.↵
   1. Volkow ND,
   2. Frieden TR,
   3. Hyde PS,
   4. Cha SS

   . Medication-assisted therapies–tackling the opioid-overdose epidemic. N Engl J Med 2014;370:2063–6.

   OpenUrlCrossRefPubMedWeb of Science
7. 7.↵
   1. Meara E,
   2. Horwitz JR,
   3. Powell W,
   4. et al

   . State legal restrictions and prescription-opioid use among disabled adults. New Engl J Med 2016;375:44–53.

   OpenUrlCrossRefPubMed
8. 8.↵
   1. Rudd RA,
   2. Seth P,
   3. David F,
   4. Scholl L

   . Increases in drug and opioid-involved overdose deaths - United States, 2010–2015. MMWR Morb Mortal Wkly Rep 2016;65:1445–52.

   OpenUrlCrossRefPubMed
9. 9.↵
   1. Mack KA,
   2. Zhang K,
   3. Paulozzi L,
   4. Jones C

   . Prescription practices involving opioid analgesics among Americans with Medicaid, 2010. J Health Care Poor Underserved 2015;26:182–98.

   OpenUrlCrossRefPubMed
10. 10.↵
    1. Han B,
    2. Compton WM,
    3. Blanco C,
    4. Crane E,
    5. Lee J,
    6. Jones CM

    . Prescription opioid use, misuse, and use disorders in U.S. adults: 2015 National Survey on Drug Use and Health. Ann Intern Med. 2017;167:293–307.

    OpenUrlCrossRefPubMed
11. 11.↵
    Council of Economic Advisers. The Underestimated Cost of the Opioid Crisis. Washington DC: Executive Office of the President of the United States; 2017.
12. 12.↵
    Original Medicare (part A and B) eligibility and enrollment. Centers for Medicare & Medicaid Services. Available from: https://www.cms.gov/Medicare/Eligibility-and-Enrollment/OrigMedicarePartABEligEnrol/index.html. Published 2015. Accessed June 6, 2017.
13. 13.↵
    Annual Statistical Report on the Social Security Disability Insurance Program, 2015. Woodlawn, MD: Social Security Administration; 2016.
14. 14.↵
    1. West GH,
    2. Dawson J,
    3. Teitelbaum C,
    4. Novello R,
    5. Hunting K,
    6. Welch LS

    . An analysis of permanent work disability among construction sheet metal workers. Am J Ind Med 2016;59:186–95.

    OpenUrl
15. 15.↵
    1. Morden NE,
    2. Munson JC,
    3. Colla CH,
    4. et al

    . Prescription Opioid use among disabled Medicare beneficiaries: intensity, trends and regional variation. Med Care 2014;52:852–9.

    OpenUrlCrossRefPubMed
16. 16.↵
    1. Unick GJ,
    2. Rosenblum D,
    3. Mars S,
    4. Ciccarone D

    . Intertwined epidemics: national demographic trends in hospitalizations for heroin-and opioid-related overdoses, 1993–2009. PLoS One 2013;8:e54496.

    OpenUrlCrossRefPubMed
17. 17.↵
    United States Department of Health and Human Services (US DHHS) CfDCaPC, National Center for Health Statistics (NCHS). Bridged-Race Population Estimates, United States, State and Country for the years 1990–2017. July 1st resident population by state, county, age, sex, bridged-race, and Hispanic origin. Compiled from 1990–1999 bridged-race intercensal population estimates (released by NCHS on 7/26/2004); revised bridged-race 2000–2009 intercensal population estimates (released by NCHS on 10/26/2012); and bridged-race Vintage 2014 (2010–2014) postcensal population estimates (released by NCHS on 6/30/2015). U.S. Census Populations with Bridged Race Categories. Retrieved from: https://www.cdc.gov/nchs/nvss/bridge_race.htm. Published online June 27, 2017. Accessed November 20, 2017.
18. 18.↵
    Centers for Medicare and Medicaid Services. CMS Statistics Reference Booklet. Available from: https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/CMS-Statistics-Reference-Booklet/index.html. Published 2016.
19. 19.↵
    1. Dufour R,
    2. Joshi AV,
    3. Pasquale MK,
    4. et al

    . The prevalence of diagnosed opioid abuse in commercial and Medicare managed care populations. Pain Pract 2014;14:E106–E115. Accessed October 26, 2017.

    OpenUrlCrossRefPubMed
20. 20.↵
    1. Song Z

    . Mortality quadrupled among opioid-driven hospitalizations, notably within lower-income and disabled white populations. Health Aff (Millwood) 2017;36:2054–61.

    OpenUrl
21. 21.↵
    1. Hedegaard H,
    2. Warner M,
    3. Minino AM

    . Drug overdose deaths in the United States, 1999–2015. NCHS Data Brief. 2017;1–8.
22. 22.↵
    Centers for Disease Control and Prevention. Vital signs: overdoses of prescription opioid pain relievers and other drugs among women–United States, 1999–2010. MMWR Morb Mortal Wkly Rep 2013;62:537–42.

    OpenUrlPubMed
23. 23.↵
    1. LeResche L,
    2. Saunders K,
    3. Dublin S,
    4. et al

    . Sex and age differences in global pain status among patients using opioids long term for chronic noncancer pain. J Womens Health (Larchmt) 2015;24:629–35.

    OpenUrlCrossRefPubMed
24. 24.↵
    1. Williams RE,
    2. Sampson TJ,
    3. Kalilani L,
    4. Wurzelmann JI,
    5. Janning SW

    . Epidemiology of opioid pharmacy claims in the United States. J Opioid Manag 2008;4:145–52.

    OpenUrlPubMed
25. 25.↵
    1. Hsu DJ,
    2. McCarthy EP,
    3. Stevens JP,
    4. Mukamal KJ

    . Hospitalizations, costs and outcomes associated with heroin and prescription opioid overdoses in the United States 2001–12. Addiction 2017;112:1558–1564.

    OpenUrl
26. 26.↵
    1. Kandel DB,
    2. Hu MC,
    3. Griesler P,
    4. Wall M

    . Increases from 2002 to 2015 in prescription opioid overdose deaths in combination with other substances. Drug Alcohol Depend 2017;178:501–11.

    OpenUrlCrossRefPubMed
27. 27.↵
    1. Glazier RE,
    2. Kling RN

    . Recent trends in substance abuse among persons with disabilities compared to that of persons without disabilities. Disabil Health J 2013;6:107–15.

    OpenUrl
28. 28.↵
    1. Seth P,
    2. Rudd RA,
    3. Noonan RK,
    4. Haegerich TM

    . Quantifying the epidemic of prescription opioid overdose deaths. Am J Public Health 2018;108:500–502.

    OpenUrlCrossRefPubMed
29. 29.↵
    1. Daniulaityte R,
    2. Juhascik MP,
    3. Strayer KE,
    4. et al

    . Overdose deaths related to fentanyl and its analogs—Ohio, January–February 2017. MMWR Morbid Mortal Wkly Rep 2017;66:904.

    OpenUrl
30. 30.↵
    1. Moyo P,
    2. Simoni-Wastila L,
    3. Griffin BA,
    4. et al

    . Impact of prescription drug monitoring programs (PDMPs) on opioid utilization among Medicare beneficiaries in 10 US States. Addiction 2017;112:1784–1796.

    OpenUrl